Global Partners SillaJen, Transgene and Lee’s Pharmaceutical Confirm Clinical Development Plan for Pexa-Vec Transgene SA Lee’s Pharmaceutical and SillaJen unveiled their late-stage clinical development plan for Pexa-Vec oncolytic immunotherapy. The companies plan to initiate a global Phase III study in the first-line treatment of advanced hepatocellular carcinoma patients, as well as several additional Phase I/II trials in different cancers, both as a single agent and in combination with a variety of other treatments, including immunotherapies such as immune checkpoint inhibitors. [Transgene SA] Press Release NeoStem Begins Research Collaboration for Treatment of Skin Wounds in Scleroderma NeoStem, Inc. announced that it has signed an agreement for a research collaboration investigating the potential of very small embryonic-like stem cells in treating difficult to heal wounds in an animal model of scleroderma. [NeoStem, Inc.] Press Release Spark Therapeutics and Genable Technologies Announce Collaboration to Advance a Gene Therapy Treatment for a Rare Form of Retinitis Pigmentosa Spark Therapeutics and Genable Technologies announced that they have entered into a collaboration agreement for Genable’s lead therapeutic to treat rhodopsin-linked autosomal dominant retinitis pigmentosa, GT038. [Spark Therapeutics] Press Release BrainStorm and Massachusetts General Hospital Sign Definitive Agreement for ALS Clinical Trial BrainStorm Cell Therapeutics announced that it has signed a definitive agreement with the Massachusetts General Hospital to conduct a Phase II clinical trial of NurOwnâ„¢ in amyotrophic lateral sclerosis (ALS), pending FDA and Institutional Review Board approvals. [BrainStorm Cell Therapeutics, Inc.] Press Release £3.5 Million Boost for Regenerative Medicine Research Programs The Loughborough University-led Center for Doctoral Training in Regenerative Medicine has been awarded £3.5 million from the Engineering and Physical Sciences Research Council and the Medical Research Council to further its research programs in the fast-growing field of the healthcare industry. [Loughborough University] Press Release Adaptimmune Announces Award of £2.1 Million from the Biomedical Catalyst Fund Adaptimmune has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. [Adaptimmune Limited] Press Release Researchers Testing Gene Therapy to Thwart Effects of Multiple Sclerosis University of Florida researchers have received a $40,000 grant from the National Multiple Sclerosis Society to test a gene therapy technique in mice that aims to help the body not treat itself like a foreign invader – a process referred to as immune tolerance – in the earliest stages of multiple sclerosis. [University of Florida] Press Release Osteoarthritis Treatment, HiQCell, Shows Continuing Significant Patient Improvements at 12 Months Post-Treatment and Beyond Regeneus announced further results from its ethics approved joint registry used to track the safety and effectiveness of its cell therapy, HiQCell®, in the treatment of osteoarthritis. [Regeneus Ltd.] Press Release ReNeuron Receives UK Regulatory Approvals for Phase II Clinical Trial in Stroke and Phase I Clinical Trial in Critical Limb Ischemia ReNeuron Group plc, a leading UK-based stem cell therapy company, announced that it has received final UK regulatory and ethical approvals to commence two new clinical trials. [ReNeuron Group plc] Press Release bluebird bio Announces First Patient Transplanted in Phase I/II Northstar Study for the Treatment of Beta-Thalassemia bluebird bio, Inc. announced that the first subject with beta-thalassemia major has been enrolled in its Phase I/II Northstar Study (HGB-204) in the United States and has undergone infusion with bluebird bio’s LentiGlobin drug product in an autologous hematopoietic stem cell transplantation. [bluebird bio, Inc.] Press Release Cellular Biomedicine Group Releases Positive Results from Phase I Clinical Trial for Hepatocellular Carcinoma Cellular Biomedicine Group, Inc. announced positive results from its Phase I clinical trial, which evaluated the safety of tumor stem cell specific dendritic cell therapy for hepatocellular carcinoma, the most common type of liver cancer. [Cellular Biomedicine Group, Inc.] Press Release STEMSOFT Announces New Website STEMSOFTâ„¢ Software Inc. announced the launch of their new website. This new website features a responsive, modern design for easy access across mobile and desktop devices, a rich user experience, and convenient access to STEMSOFT product information, news and events. [STEMSOFTâ„¢ Software Inc.] Press Release |